乳房重建植入物表面纹理与乳腺癌复发的关联
该单中心队列研究纳入650例乳腺癌患者(687例重建),比较光滑与毛面植入物重建后的肿瘤学结局,中位随访52个月。毛面植入物与更低的DFS显著相关(HR 3.054),在ER阳性、浸润性癌及晚期肿瘤中更明显,LRRFS无显著差异。
要点
- 毛面植入物重建与乳腺癌DFS降低显著相关(HR 3.054)。
- ER阳性、浸润性癌及II-III期患者中关联更显著。
- 局部区域无复发生存率在两组间无显著差异。
核心结论
- 乳房重建使用毛面植入物可能与乳腺癌复发相关。
- 该关联需进一步研究验证。
研究设计与样本
- 韩国三星医疗中心单中心队列研究,2011年至2016年接受全乳切除及即刻两阶段组织扩张器/植入物重建的乳腺癌患者。
- 共650例患者(687例重建),平均年龄43.5岁,中位随访52个月。
- 按植入物表面类型分为光滑植入物组(274例,39.9%)和毛面植入物组(413例,60.1%)。
主要发现
- 5年局部区域无复发生存率为96.7%,5年无病生存率为95.2%。
- 与光滑植入物相比,毛面植入物与更低的无病生存率显著相关(HR 3.054;95% CI 1.158-8.051;P = .02)。
- ER阳性患者中关联显著(HR 3.130;95% CI 1.053-9.307;P = .04),浸润性癌患者中亦显著(HR 3.044;95% CI 1.152-8.039;P = .03)。
- 晚期(II或III期)肿瘤中关联更显著(HR 8.874;95% CI 1.146-68.748;P = .04)。
- 局部区域无复发生存率在两组间无统计学显著差异。
临床怎么用
- 乳腺癌重建选择植入物表面类型时,应综合考虑肿瘤分期、ER状态及复发风险。
- 对ER阳性、浸润性癌或晚期肿瘤患者,使用毛面植入物需谨慎评估获益与风险。
局限性
- 单中心回顾性队列研究,可能存在选择偏倚和未测量混杂因素。
- 随访时间有限,需更长期数据验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The potential association between breast implant-related anaplastic large cell lymphoma (BIA-ALCL) and implant texture has raised concerns about the additional unexpected adverse effects of textured implants, including potentially adverse outcomes for other cancers. In addition to the risk of developing BIA-ALCL, breast cancer survivors may worry about whether the type of implant inserted is associated with recurrence of their original cancer-an issue for which little evidence currently exists. OBJECTIVE: To evaluate the oncologic outcomes of breast cancer according to the surface type of implants used for reconstruction and to identify the independent factors associated with breast cancer recurrence and survival, including implant surface type. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted at Samsung Medical Center, a single tertiary referral center in Seoul, South Korea. Patients with breast cancer who underwent total mastectomy and immediate 2-stage tissue expander/implant reconstruction between January 1, 2011, and December 31, 2016, were identified from a prospectively maintained database. Patients were categorized into 2 groups according to the surface type of implant used for their reconstruction (smooth or textured implant). These patients were followed up for at least 2 years after insertion of the implant. Data analysis was performed from February 15, 2020, to March 5, 2020. EXPOSURES: Use of smooth implants vs textured implants at the second-stage operation. MAIN OUTCOMES AND MEASURES: The main outcomes of interest were local and regional recurrence-free survival (LRRFS) and disease-free survival (DFS) rates. Cumulative incidence of oncologic events in the smooth implant and textured implant groups and their respective hazard ratios (HRs) were collected and updated regularly. RESULTS: In total, 650 patients (all women, with a mean [SD] age of 43.5 [7.4] years), representing 687 cases, met the inclusion criteria and were followed up for a median (range) duration of 52 (31-106) months. Of the 687 cases, 274 (39.9%) received a smooth implant and 413 (60.1%) received a textured implant. Patients in these 2 surface texture groups had similar characteristics, including tumor staging (stage I: 102 [37.2%] vs 173 [41.9%]; stage II: 93 [33.9%] vs 119 [28.8%]; stage III: 14 [5.1%] vs 20 [4.8%]; P = .50) and rates of adjuvant radiotherapy (42 [15.3%] vs 49 [11.9%]; P = .19) and chemotherapy (113 [41.2%] vs 171 [41.4%]; P = .97). The 5-year LRRFS was 96.7%, and the 5-year DFS was 95.2%. Compared with the use of a smooth implant, textured implant use was statistically significantly associated with lower DFS, and this difference remained significant after adjusting for estrogen receptor (ER) status and tumor stage (HR, 3.054; 95% CI, 1.158-8.051; P = .02). Similar statistically significant associations were observed on multivariable analysis of patients with ER-positive cancer (HR, 3.130; 95% CI, 1.053-9.307; P = .04) and those with invasive cancer (HR, 3.044; 95% CI, 1.152-8.039; P = .03). The association of textured implant use with recurrence (lower DFS) was more prominent in cases with late-stage (stage II or III) tumor (HR, 8.874; 95% CI, 1.146-68.748; P = .04). The LRRFS did not differ statistically significantly according to implant surface texture. CONCLUSIONS AND RELEVANCE: This cohort study found that use of textured implants in reconstruction appears to be associated with recurrence of breast cancer. Further investigation is required to verify these results.
引用
- Lee KT, Kim S, Jeon BJ, et al. Association of the Implant Surface Texture Used in Reconstruction With Breast Cancer Recurrence. JAMA Surg. 2020. PMID: 33026424. doi:10.1001/jamasurg.2020.4124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。